>
The syringe and needle market are observing a burgeoning need for expanding universal population, the necessity for blood collection, vaccinations, & injectable medications, as well as other factors.
Mechanical Progressions: The market is being changed by improvements in syringe and needle advances. Security highlights, canny needles, and accuracy infusion instruments are collecting foothold as advancements that work on tolerant wellbeing and medical care effectiveness.
The rising rate of ongoing infections, like diabetes and cardiovascular problems, is significantly driving the interest for the injectable drugs and accordingly propelling market growth.
The COVID-19 epidemic has notably altered market dynamics, resulting in an exceptional demand for syringes to accelerate mass vaccination campaigns. To meet immunization goals, state run administrations and medical care associations overall are putting resources into needle creation development.
The increased emphasis on healthcare professional and patient safety can be attributed to the augmented use syringes and needles that are safety-engineered. It is anticipated that regulatory agencies will continue this trend by placing a high priority on secure injection methods.
A Rising Geriatric Populace: A significant element affecting business sector patterns is the maturing of the worldwide populace. Injectable prescriptions are often expected by the older, bringing about a continuous interest for syringes and needles. It is awaited that this demographic turn will drive market expansion in the forthcoming years.
The market is being substantially pushed forward by the mounting emphasis placed on international vaccination programs, particularly those in the developing nations. This includes efforts to combat infectious diseases and improve public health.
The market is encountering development because of the rising use of biologics and biosimilars, which every now and again require injectable organization. The rising commonness of these refined medicines is driving a flood in the requirement for specific syringes and needles.
Natural manageability is affecting business sector elements, as proven by the rising reception of recyclable and eco-accommodating materials in the development of syringes and needles. This example compares with the general supportability targets of the medical care area.
Troubles in the Production network: Especially during the pandemic, the syringe and needle market has experienced hardships related with inventory network interruptions. In order to ensure that these essential medical devices are distributed consistently and effectively, ongoing efforts are being made to strengthen and expand supply chains.
The market keeps on being affected by rigid administrative guidelines that oversee clinical gadgets, like needles and needles. To guarantee item quality and wellbeing and to consent to administrative necessities, producers are subsidizing consistence measures.
Market expansion fuelled by partnerships and collaborations: Needle producers, drug organizations, and medical services suppliers are framing a rising number of associations and coordinated efforts. These alliances' primary goals are to speed up the supply chain, improve distribution networks, and address the rising demand for injectable therapies.
Report Attribute/Metric | Details |
---|---|
Market Opportunities | Businesses are spending more on R&D, intending to create high-quality, innovative goods. |
Market Dynamics | The fast improvement of technology in syringe and needle administration technologiesRising vaccination needs and technological advances in syringe and needle systems |
Syringe and Needle Market Size was estimated at USD 9.31 Billion in 2023. The Syringe and Needle market industry is projected to grow from USD 9.85 Billion in 2024 to USD 14.74 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.16% during the forecasted timeframe (2024 - 2032). Rising vaccination needs and the fast improvement of technology in drug delivery platforms are the key market drivers contributing to the market’s growth and revenue.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Becton Dickinson (BD) continued to dominate the syringe and needle market in 2023, mainly within the hospital segment, with more than half of total sales. Their production capacity was so high that they could easily supply syringes at competitive prices. BD's portfolio of products includes hypodermic needles with SafetyGlide™ shielding, injection needles Eclipse™ pivoting, and retractable syringes Integra™.
Wuxi Biologics global contract research, development and manufacturing organization (CRDMO) launched Good Manufacturing Practice (GMP) operation of its new drug product facility DP5 located in Wuxi, China in June 2022. The facility is designed to enable different volume delivery options for pre-filled syringes (PFS).
Roche diabetes care introduced ACCU-FINE pen needles for painless delivery of insulin in May 2022. This helps in easy delivery of insulin thereby leading to better management of diabetes among diabetic patients. These actions are expected to contribute towards growing the market over the period under review.
UniSafe 1mL safety device for pre-filled syringes has been approved as a combination product in Asia by Owen Mumford Pharmaceutical Services Ltd since February 2022.
The rising vaccination need drives Market CAGR for syringe and needle. Recently, there has been an increase in the need for the production of syringes and needles. As a result, it constitutes one of the primary drivers of this industry. Aside from that, tremendous technical improvements inside the twenty-three-inch syringe and needle drug injection equipment are propelling this industry to new heights. Furthermore, as injectable medications are superior to oral treatments, their demand is constantly growing.
Additionally, with the increasing prevalence of long-term and infectious diseases and the increased usage of injectable medications, the syringe and needle sector has experienced rapid expansion. The healthcare system is under enormous strain as the frequency of long-term diseases such as cardiovascular disease, diabetes, and cancer rises. According to the American Heart Association report published in 2019, CVD is still the top cause of mortality globally, accounting for roughly 19.8 Mn fatalities that year. This figure is predicted to exceed 25.8 Mn by 2030. Moreover, Organizations are learning about them from beginning to end distribution networks to lower the cost of goods while improving the standard of goods and amenities related to disposable syringes. These operational approaches assist organizations in saving money by avoiding third-party costs. These qualities are expected to provide profitable market growth opportunities.
The COVID had little impact on the medical supply business. The healthcare and medical equipment sectors worked harder than normal. However, the industrial speed was slowed as the workforce deteriorated throughout that time frame. Producers have increased their syringe and needles manufacturing facilities to increase the supply of the COVID-19 vaccine. The growing involvement of community members and chemists in chronic disease management and an emphasis on drug adherence during the COVID-19 pandemic has reduced the strain on healthcare systems. For example, the US government has entered into a USD 138 million agreement with key syringe makers to expedite the production of one hundred million needles for COVID-19 vaccinations.
For instance, based on the GLOBOCAN 2020 estimate, the overall number of cancer-related cases in the globe in 2020 would be about 19,292,789 occurrences. The total amount of cases will increase to 28,887,940 through 2040. The increasing incidence of cancer cases causes a need for needles and syringes for medication administration, contributing considerably to the market's growth during the projected timeframe. Therefore, it is expected that throughout the projected timeframe, demand for syringes and Needles will increase due to the rising vaccination need. Thus, driving the Syringe and Needle market revenue.
The syringe and needle market segmentation, based on type, includes blood collection syringes and needles, ophthalmic syringes and needles, bone marrow syringes and needles, and catheter syringes and needles. Catheter syringes and needles category dominated the market, accounting for 39% of the market share (USD 2.7 Billion) in 2022. In emerging economies, category growth is driven by expanding chronic diseases for which treatments are supported by public and private healthcare organizations, which will boost the market's overall growth.
The syringe and needle market segmentation, based on application, includes general surgery, diagnostic, respiratory, orthopedics, cardiovascular, and dental. The general surgery category generated the highest revenue of about 43% (USD 3.8 billion) in 2022. It is because hospitals generate a huge need for syringes and needles required to increase surgeries demand which will boost market growth and revenue.
The syringe and needle market segmentation, based on usability, includes disposable and reusable. Disposable syringe and needle dominated the market, accounting for 80% of the market share (USD 9 Billion) in 2022. Reusable syringes are typically more costly than disposable syringes. Both have different uses for medical procedures. However, disposable ones are in greater demand than those that are reusable.
Figure 1: Syringe and Needle Market, by Usability, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Syringe and Needle market area is estimated to grow rapidly during the projected timeframe, owing to an increase in cardiac problems and diabetes leading to the development of innovation in syringes and needles products. In addition, the growing number of diseases prevalence in the North American region will boost the market growth.
Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Syringe and Needle Market Share by Region 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe region’s Syringe and Needle market will dominate due to increasing need and demand for syringes and needles sales, generating higher revenue during the projected timeframe. Further, the German Syringe and Needle market dominates the market share, and the UK Syringe and Needle market is anticipated to expand quickly in the European region.
The Asia-Pacific Syringe and Needle Market accounts for the second-highest market share during the projected timeframe. This is due to several government programs aimed at encouraging the utilization of disposable healthcare products to reduce transmission, along with the existence of important market players in the region, which are anticipated to enhance the market growth in the APAC region. Moreover, China’s Syringe and Needle market holds the largest market share, and the Indian Syringe and Needle market is anticipated to grow in the Asia-Pacific region during the projected timeframe.
Syringe and Needle Key Market Players & Competitive Insights
Leading market players invested heavily in research and development (R&D) to scale up their manufacturing units and product lines, which will help the Syringe and Needle market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with important market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Syringe and Needle industry must offer cost-effective and sustainable options to survive in a dynamic market.
Manufacturing locally to minimize operational expenses is a key business strategy manufacturers use in the Syringe and Needle industry to benefit customers and capture untapped market share and revenue. The Syringe and Needle industry has recently offered significant advantages to the medicine and service industry. Major players in the Syringe and Needle market, including DeRoyal, Albert David Ltd, B. Braun Melsungen AG, Terumo Corporation, Connecticut Hypodermics Inc., Insulet, Septodont, Medtronic, BD, Schott AG, Cardinal Health, and Smiths Medical, are attempting to expand market share and demand by investing in research and development (R&D) operations to produce sustainable and affordable solutions.
WuXi Biologics, From concept through the product's commercial, is now a truly worldwide single-source pharmaceutical technology platform. It was founded in 2010 and began developing the expertise and infrastructure needed for biologics research and development (R&D) and GMP manufacture. In June 2017, it got listed on the Hong Kong Stock Exchange. Wuxi Biologics, a contractual research and development (R&D) and production organization (CRDMO) began Exemplary Production practice operations at its newly constructed pharma product factory DP5 in Wuxi (China) in June 2022. With already-filled syringes, the factory provides many volume delivery choices.
HTL STREFA is an international company with over 80 years of expertise. They are the world's top provider of blood micro-sampling instruments for medicine. It is devoted to producing safeguards that reduce or eradicate the danger of blood-borne infections. They use an ongoing improvement method to analyze and upgrade goods, develop changes, and introduce novel approaches in response to evolving patient and medical professional demands. They strive to meet the most stringent sanitary and sterile requirements. Their manufacturing process is characterized by ergonomics, which is simplicity and dependability. HTL-STREFA announced Droplet MicronTM on the 22nd of September 2020 as an updated needle and syringe with an improved design that will enhance the process of injection experience.
Key Companies in the Syringe and Needle market include
Syringe and Needle Industry Developments
June 2022:Wuxi Biologics, a contractual research and development (R&D) and production organization (CRDMO), began Exemplary Production practice operations at its newly constructed pharma product factory DP5 in Wuxi (China) in June 2022. With already-filled syringes, the factory provides many volume delivery choices.
2021:Olympus Corporation US will release the FDA-approved BF-UC190F endobronchial ultrasound bronchoscope in 2021 for partial or non-invasive cancer of the lung detection and treatment by needle biopsies.
September 2020:HTL-STREFA announced Droplet MicronTM on the 22nd of September 2020 as an updated needle and syringe with an improved design that will enhance the process of injection experience.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)